NTLA Stock Price History and Quote Analysis: Insights for Investors
Intellia Therapeutics, Inc.
Stock Price Today
Intellia Therapeutics, Inc. (NTLA) stock declined over -0.81%, trading at $17.70 on NASDAQ, down from the previous close of $17.84. The stock opened at $17.75, fluctuating between $17.46 and $18.00 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 526 |
| Beta | 1.765 |
| Sales or Revenue | $36.28M |
| 5Y Sales Change% | -0.422% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Intellia Therapeutics, Inc. (NASDAQ: NTLA) stock price is $17.70 in the last trading session. During the trading session, NTLA stock reached the peak price of $18.00 while $17.46 was the lowest point it dropped to. The percentage change in NTLA stock occurred in the recent session was -0.81% while the dollar amount for the price change in NTLA stock was -$0.15.
The NASDAQ listed NTLA is part of Biotechnology industry that operates in the broader Healthcare sector. Intellia Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. David Lebwohl M.D.
Executive Vice President & Chief Medical Officer
Dr. Jennifer A. Doudna Ph.D.
Founder & Member of Scientific Advisor Board
Mr. Nessan Bermingham Ph.D.
Founder & Member of Scientific Advisor Board
Dr. John M. Leonard M.D.
Pres, Chief Executive Officer & Director
Mr. Glenn G. Goddard CPA
Executive Vice President, Chief Financial Officer & Treasurer
Dr. Andrew May
Founder and Member of Scientific Advisor Board
Dr. Laura Sepp-Lorenzino Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. James E. Basta Esq., J.D.
Executive Vice President, Gen. Counsel & Corporation Sec.
Dr. Derrick J. Rossi Ph.D.
Founder & Member of Scientific Advisor Board
Mr. Derek Hicks
Executive Vice President & Chief Bus. Officer
NTLA's closing price is 2.35% higher than its 52-week low of $17.43 where as its distance from 52-week high of $34.87 is -48.84%.
Number of NTLA employees currently stands at 526.
Official Website of NTLA is: https://www.intelliatx.com
NTLA could be contacted at phone 857 285 6200 and can also be accessed through its website. NTLA operates from 40 Erie Street, Cambridge, MA 02139, United States.
NTLA stock volume for the day was 1.49M shares. The average number of NTLA shares traded daily for last 3 months was 1.43M.
The market value of NTLA currently stands at $1.80B with its latest stock price at $17.70 and 101.58M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com